<DOC>
	<DOCNO>NCT02250599</DOCNO>
	<brief_summary>The present study randomize , control , multicenter phase II study metastatic nasopharyngeal carcinoma ( NPC ) treat evacizumab ( AVASTIN , Roch ) paclitaxel carboplatin regimen ( TC+AVASTIN ) carboplatin/paclitaxel alone ( TC ) . The population consist metastatic nasopharyngeal carcinoma ( NPC ) fail radical radiotherapy chemotherapy-naïve advance NPC ( stage IV ) . The effectiveness side effect evaluate accord RECIST 1.1 NCI-CTC AE V4.0.TEORTC QLQ-C30 EORTC QLQ-H &amp; N35 use measure PRO outcome study .</brief_summary>
	<brief_title>Efficacy Safety TC+AVASTIN Versus TC Patients With Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Nasopharyngeal carcinoma vastly common East Asia , especially China high incidence , number new case account 40 % world total . The disease involve population maybe 4 million world . More 2700-3000 new nasopharyngeal carcinoma patient diagnose SUN YAT-SEN university cancer center every year . It common 40-50 year old adult top ten ( 10th ) malignant tumor Chinese male threaten human health social economy . Chemotherapy standard treatment advance nasopharyngeal carcinoma.Several phase II study also confirm effectiveness paclitaxel carboplatin （TC） regimen advance NPC , maybe simple right choice . Increasing expression VEGF serum associate poor prognosis metastatic nasopharyngeal carcinoma . Agents selectively target VEGF-A receptor show significant antitumor effect xenograft model nasopharyngeal . Studies demonstrate bevacizumab（AVASTIN） administration chemotherapy chemoradiation feasible patient nasopharyngeal cancer . Bevacizumab safely combine range cytotoxic anticancer agent include TC regimen . Evidence indicate potential possibility TC+AVASTIN regimen may superior TC regimen .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must meet follow criterion study entry : Age ≥ 18 Eastern Cooperative Oncology Group ( ECOG ) performance status 0~1 Patients life expectancy &gt; 12 week Histologically proven NPC diagnosis Metastatic nasopharyngeal carcinoma evidence unsuitable local treatment ( term relevant therapy antitumor like surgery , radiofrequency ablation , transcatheter arterial chemoembolization ( TACE ) radiotherapy ( except palliative radiotherapy metastatic bone pain appropriate radiation dosage without influence hemogram ) , etc . ) Neoadjuvant concurrent chemoradiotherapy allow , provide treatment complete least 3 month start study drug treatment ≥1 measurable target base RECIST criterion Adequate bone marrow , hepatic renal function , define follow within 1 week prior randomization Patients must sign study specific informed consent prior registration Patient must recover ( &gt; 28 day postsurgery ) effect surgery , postoperative infection , complication initial treatment bevacizumab Systolic blood pressure ≤ 160 mmHg diastolic pressure ≤ 90 mmHg within 7 day prior randomization . Prior systemic treatment metastatic nasopharyngeal carcinoma Preparing receive local treatment metastatic nasopharyngeal carcinoma ( exclude palliative irradiation release skeletal pain ) Prior treatment bevacizumab agent specifically target VEGF Patients hemorrhage tendency include acute hemorrhage digestive tract , nasal bleed （not include nasal epistaxis ) , continuous hemorrhagic disease Coagulation function disorder disease . Patients use known NSAIDS inhibit platelet . Patients gross hemoptysis hematemesis ( define bright red blood 1 teaspoon frank clot within minimal phlegm per cough episode ) within 4 week prior registration ; patient incidental blood mixed phlegm exclude Patients receive experimental therapeutic cancer treatment Severe , active comorbidity , define follow : i.Unstable angina and/or congestive heart failure vascular ( e.g . aortic aneurysm require surgical repair peripheral thrombosis ) disease require hospitalization within last 12 month , cardiac compromise ( e.g . inadequately controlled cardiac arrhythmia ) judgment investigator preclude safe administration study drug ; Patient must show sign recent myocardial infarction ischemia finding ST elevation ≥ 2mm EKG ii.History arterial thromboembolic event , venous thromboembolism &gt; NCI CTCAE Grade 3 , transient ischemic attack ( TIA ) , cerebral vascular accident ( CVA ) , transmural myocardial infarction ( MI ) , hypertensive crisis hypertensive encephalopathy iii.History ongoing bleed diathesis , hemorrhagic disorder , coagulopathy iv.Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy within 30 day prior registration v.History abdominal fistula , gastrointestinal perforation , intraabdominal abscess , active GI bleeding within last 6 month prior registration ; vi.Esophageal varix , nonhealing ulcer , nonhealing wound , bone fracture within last 6 month prior registration vii.Active , untreated infection and/or acute bacterial fungal infection uiring intravenous antibiotic time registration viii.Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition ; ix . Hepatic insufficiency result clinical jaundice and/or coagulation defect x . Minor surgical procedure include placement vascular access device , within 2 day first study treatment Patients currently ( within 10 day study enrollment ) take warfarin , heparin , daily treatment aspirin ( &gt; 325 mg/day ) , nonsteroidal antiinflammatory medication know inhibit platelet function ; treatment dipyramidole , ticlopidine , clopidogrel , cilostazol Pregnancy woman childbearing potential men sexually active willing/able use medically acceptable form contraception ; Prior allergic reaction study drug ( ) involve protocol Contraindication Bevacizumab Patients another cancer history （not NPC）within 5 year randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Metastatic Nasopharyngeal Carcinoma</keyword>
	<keyword>treatment</keyword>
</DOC>